Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,761 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Major Depressive Disorder
Interventions: Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation, Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC; Device · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depressive Disorder
Interventions: saredutant (SR48968), placebo, escitalopram; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years to 64 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Depressive Disorder
Interventions: Open-label TMS; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depressive Disorder, Major
Interventions: Duloxetine, Vortioxetine; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9,586 participants
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression, Psychotic Disorders, Depressive Disorder, Major
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depressive Disorder, Major
Interventions: Navigated Transcranial Magnetic Stimulation; Device
Lead sponsor: Magstim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Atlanta, Georgia • Dunwoody, Georgia

Conditions: Major Depressive Disorder
Interventions: LPS, Saline; Biological
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Major Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Warfarin, LY2216684; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: RX-10100; Drug
Lead sponsor: Rexahn Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Cerritos, California • Escondido, California • Los Angeles, California + 38 more

Conditions: Major Depressive Disorder
Interventions: Active - HD tDCS, Sham - HD tDCS; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anxiety Disorders, Depressive Disorders, Eating Disorders, Obsessive Compulsive Disorder
Interventions: Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications; Drug
Lead sponsor: Duke University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: TMS; Device
Lead sponsor: Neuronetics; Other
Eligibility: 15 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: New York, New York • Charlotte, North Carolina • Spokane, Washington

Conditions: Major Depressive Disorder
Interventions: Behavioral activation plus mobile app, Standard behavioral activation; Behavioral
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: North Little Rock, Arkansas

Conditions: Major Depressive Disorder, Traumatic Brain Injury
Interventions: Active, Sham; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: desvenlafaxine succinate sustained-release, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more

Conditions: OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions: Serotonergic Psychedelic, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Hamden, Connecticut • West Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: SR58611A; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Treatment Resistant Depression
Interventions: Prefrontal Cortical Stimulation (PCS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 22 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 44
States / cities: Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more

Conditions: Major Depression, Post Traumatic Stress Disorder
Interventions: SM-001; Drug
Lead sponsor: Advanced Integrative Medical Science Institute; Other
Eligibility: 25 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Major Depression With Psychotic Features
Interventions: quetiapine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Schizo Affective Disorder
Interventions: FOCUS participants; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: St Louis, Missouri • Dover, New Hampshire • Manchester, New Hampshire

Conditions: Major Depressive Disorder (MDD)
Interventions: RX-10100; Drug
Lead sponsor: Rexahn Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Denver, Colorado • Atlanta, Georgia • Rockville, Maryland

Search by objective public record fields.

Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

In-patient SCC TMS

Combining Data Sources to Identify Effect Moderation for Personalized Mental Health

Clinical and Biological Characteristics of Psychotic Depression

Coil Positioning in Navigated Transcranial Magnetic Stimulation Feasibility in Depression Patients Trial

Neural Response to Inflammatory Challenge in Major Depressive Disorder

Brain Inflammation in Major Depressive Disorder Background

A Study of LY2216684 and Warfarin in Healthy Subjects

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

Transcranial Direct Current Stimulation (tDCS) Therapy in Major Depression

Antidepressant Safety in Kids Study

Accelerated TMS for MDD

Mobile Apps for the Treatment of Depression

fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

PCS in Severe Treatment Resistant Depression

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

Treatment of Depression With Quetiapine

Technology-Assisted Implementation of a Mobile Health Program for Serious Mental Illness

Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)